The ability of structurally distinct ligands to ''bias'' G protein-coupled receptor signaling affords the opportunity to tailor efficacy to suit specific therapeutic needs. Furness et al. demonstrate that ligand structure controls not only which effectors are activated, but also the way they are activated and the kinetics of downstream signaling.
Two key tenets guiding G protein-coupled receptor (GPCR) drug discovery research are ''pluridimensional'' efficacy, the concept that GPCRs signal by engaging multiple G protein and non-G protein effectors (Galandrin et al., 2007) , and ''functional selectivity'' or ''ligand bias,'' the concept that ligand structure is an important determinant of which effector pathway(s) are engaged (Kenakin and Christopoulos, 2013) . How are these feats accomplished? Current models predict that ligand-specific signaling patterns emerge because of differences in the efficiency with which ligands stabilize the structural conformations that couple the receptor to each of its possible downstream effectors. Consider the case of ''conformational selection,'' in which two ligands activate a single receptor, which itself can engage two different downstream effectors ( Figure 1A ). Assuming that the ''active'' receptor conformation that most efficiently couples it to one effector differs from that which optimally engages another, structurally distinct ligands can ''bias'' the strength of signaling in each pathway by stabilizing these discrete active states in different proportions. While this model accounts for ligand bias with respect to which effectors are activated, it does not imply that different ligands can activate the same effector in fundamentally different ways. In the current issue of Cell, Furness et al. (2016) establish a new concept in GPCR pharmacology by showing exactly that.
GPCR signaling commences when an agonist-bound receptor binds to and catalyzes GTP for GDP exchange within a heterotrimeric G protein alpha subunit, permitting the latter to activate second messenger-generating effectors. Focusing on activation of the adenylyl cyclase stimulatory G protein Gs and cAMP production, the authors study the effects of two naturally occurring ligands for the human calcitonin receptor (CTR), human calcitonin (hCT) and salmon calcitonin (sCT). The data reveal that hCT and sCT differentially modulate Gs-cAMP signaling by producing ligand-specific conformational changes in Gs that alter the guanine nucleotide affinity of the ligand-CTR-Gs ternary complex. Native PAGE measuring CTR-Gs complex assembly shows that while sCT is 10-fold more effective at recruiting the Gs heterotrimer, the hCT-occupied CTR-Gs complex is 10-fold more susceptible to disruption by GTP. Such results are thermodynamically possible only if the Gs heterotrimer adopts different conformations when bound to the hCT-CTR and sCT-CTR complexes. Bioluminescent and fluorescent resonance energy transfer measurements reporting ligandand GTP-induced conformational rearrangements in the Gs heterotrimer further support this conclusion.
Importantly, hCT promotes a faster rate of Gs-GTP association than sCT, something that should equate to faster Gs turnover and more efficient activation of adenylyl cyclase. This hypothesis is tested using chimeric calcitonin peptides that permit the stability of the ligand-CTR interaction to be varied independent of their G protein activating properties. The results show that the difference in Gs activation potency is not driven by ligand offrate but by ligand-induced differences in Gs conformation. Using total internal reflection microscopy to assess the effect of ligand stimulation on G protein mobility, the authors then directly demonstrate that Gs turnover is faster for the hCT-bound receptor than for the sCT-bound receptor. As expected, this differential translates into more rapid accumulation of cAMP in cells at submaximal concentrations of hCT compared to sCT. Collectively, these results support a model in which the hCTbound CTR promotes faster GTP binding and more rapid Gs turnover, allowing for more rapid signaling ( Figure 1B) .
This work extends the concept of conformational selection at the level of the ligand-GPCR complex to one that includes conformational selection at the level of the ligand-GPCR-G protein complex. The idea that ligands can influence not only which effectors are activated, but also how they are activated, is supported by recent work on another GPCR effector, the arrestins. The ubiquitous arrestins are recruited to activated GPCRs, whereupon they mediate desensitization, uncoupling the receptor and G protein, and additionally act as signaling scaffolds (Luttrell and Gesty-Palmer, 2010) . Recent biophysical studies demonstrated that GPCRs impose characteristic arrestin ''conformational signatures'' and that ligand structure is an important factor in determining arrestin conformation (Nuber et al., 2016; Lee et al., 2016) . Conformational changes within the bound arrestin influence both the avidity of GPCR-arrestin binding and arrestin engagement of downstream signals, such that the ligand-specific arrestin conformation reflects its downstream function. Taken in concert with the findings reported here, the view emerges that ligand binding initiates a wave of conformational changes that are transmitted through the receptor to impose functionally distinct conformations on intracellular effectors.
Beyond providing novel insights into the molecular mechanisms of GPCR signaling, this evolving understanding of GPCR signaling efficacy has important implications for drug discovery. GPCRs, which were originally envisioned as simple detectors of hormones and neurotransmitters in the extracellular environment (Ahlquist, 1948) , then as binary switches whose proportional distribution in the ''off'' and ''on'' states is determined by the intrinsic efficacy and concentration of agonist ligands (Samama et al., 1993) , have come to be viewed more broadly as components of an allosterically regulated signal transduction machinery whose function is to bind molecules (extracellular ligands) at one location and change shape to affect the binding and conformation of other molecules (intracellular effectors) at another location (Kenakin, 2012) . In this context, Furness et al. (2016) provide us with fundamental information about how GPCRs transmit the information encoded in ligand structure to downstream effectors and broaden the scope of GPCR efficacy to include the capacity to engender different ''activation modes'' of intracellular effectors. The capacity of ligand structure to ''bias'' both GPCR coupling to different effectors and the kinetics of downstream effector signaling affords ever greater opportunity to tailor GPCR efficacy to suit specific therapeutic needs. While the expression pattern of receptors will always determine which tissues are targeted, it is clear that ligand structure can influence how those cells respond, creating in biased ligands the potential to selectively activate beneficial signals while repressing potentially deleterious ones. Who ever thought GPCR pharmacology could be so nuanced? Furness et al. (2016) , human and salmon calcitonin (CT) binding to calcitonin receptor produces different conformations in the receptor-bound Gs heterotrimer (a,b, and g), influencing the rate of GTP exchange and thereby the efficiency with which the CTR stimulates cAMP production. This form of ligand ''bias'' affects the kinetics of downstream pathway activation.
